
A study examined the efficacy and safety of intravenous fosphenytoin, a prodrug of phenytoin, in treating acute zoster-associated pain. The study was conducted at 13 medical institutions, a phase II trial involving inpatients with insufficient relief from nonopioid analgesics. Patients received a single intravenous dose of fosphenytoin (high or low) or placebo. Despite discontinuation due to COVID-19, results indicated fosphenytoin significantly reduced pain compared to placebo. Treatment-emergent adverse events raised no safety concerns. Intravenous fosphenytoin emerges as a promising alternative for managing acute zoster-associated pain.
Like
Save
Share